<DOC>
	<DOC>NCT02919501</DOC>
	<brief_summary>To evaluate the early onset of efficacy of vortioxetine 17 mg intravenously (IV) and vortioxetine 10 mg/day oral dose regimen versus vortioxetine 10 mg/day oral dose regimen on depressive symptoms To evaluate the early onset of efficacy of vortioxetine 17 mg IV and vortioxetine 10 mg/day oral dose regimen versus vortioxetine 10 mg/day oral dose regimen on - global clinical impression - anxiety symptoms To determine population pharmacokinetic parameters of vortioxetine</brief_summary>
	<brief_title>Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>The patient has recurrent Major Depressive Disorder (MDD), diagnosed according to Diagnostic and Statistical Manual for Mental Disorders, 5th Edition (DSM5™), classification code (296.3x). The recurrent Major Depressive Episode (MDE) should be confirmed using the MiniInternational Neuropsychiatric Interview (MINI). The patient has a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥30 at both Screening and Baseline Visits. The patient has had the current MDE for ≥3 months The patient has any current psychiatric disorder or Axis I disorder (DSM5™ criteria), other than MDD, as assessed using the Mini International Neuropsychiatric Interview (MINI). The patient has a current diagnosis of history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features (DSM5™ criteria). The patient suffers from personality disorders, intellectual disability, pervasive development disorder, attention deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM5™ criteria). The patient has a history of lack of response to previous treatment with vortioxetine (including current episode). Other Protocol defined inclusion and exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>